Chelsie Derman

In an interview, Paul Appelbaum, MD, discussed issues clinicians will need to bring up to their patients if the FDA approves a psychedelic-assisted therapy.

In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.

In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.

In an interview with Andrew Chen, MD, he discussed the first-line treatment for generalized anxiety disorder and when to take other alterative medication.

A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.

This sleep month in review features positive pipeline updates and treatments for improved sleep quality.

This month in review features top psychiatry news in the pipeline, FDA approvals, and a piece for autism awareness month.

The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.

FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.

A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.

In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.

Many parents experience high levels of isolation, loneliness, and burnout, feeling like there is no one to talk to about their struggles in their daily lives.

Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment.

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

The fracture risk is greater for nursing home residents with dementia, greater baseline blood pressure values, and no recent antihypertensive medication use, a new study found.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.

A new study found female patients (8.15%) had a lower mortality rate when treated by female physicians than male physicians (8.38%).

A new study found the perceived onset of old age rose nearly 3 years from 1911 to 1953.

A poll found people were more likely to use alternate health care sites if they were women, aged 50 – 64 over 65 – 80 years, and had a household income of < $60,000.

A new study found an intervention targeting proton pump inhibitor overuse was linked to an absolute reduction of 7.3%.

A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.

In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.

A new study found individuals with PTSD face rapid transitions between neutral and negative emotional states.

A new study explored increased health care utilization of children among several specific sleep disorders, race, and age.

Patients with a delayed appendicitis diagnosis had 1.23 times increased hospital care costs, and Black patients had a greater increased cost than White patients.

In an interview with HCPLive, Sunny Rai, PhD, shed light on a new study regarding how an AI model failed to detect depression in Black individuals.

A new study showed secukinumab was not superior to Sandoz adalimumab (SDZ-ADL; TNF inhibitor) in terms of similar low rates of radiographic progression and safety profiles.

A new study found extending postpartum Medicaid from 60 days to 12 months is linked to new mothers being more likely to seek mental health care for perinatal mood and anxiety disorders.